Sartorius swings to H1 FY26 net profit of €122.2 million; revenue rises 2.5% to €1.81 billion

• Sartorius Stedim Biotech posted H1 net profit of €122.2 million, up 50.9% year over year, as sales revenue rose 2.5% to €1.81 billion.
• Underlying EBITDA increased 3.9% to €547.8 million, lifting the margin by 0.5 percentage points to 30.3%.
• Operating profit (EBIT) climbed 18% to €317.9 million as extraordinary items narrowed to -€20.1 million.
• Free cash flow rose 70.4% to €207.7 million; net debt edged up to €3.76 billion from year-end 2025.
• Management reiterated 2026 guidance for sales revenue growth of 5% to 9% and underlying EBITDA margin slightly above 30%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sartorius Stedim Biotech SA published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.